Mersana Therapeutics to effect 1-for-25 reverse stock split to regain Nasdaq compliance

Mersana Therapeutics, Inc.

Reverse stock split ratio set at 1-for-25; effective July 25, 2025 at 5:00 p.m. ET.
No fractional shares issued; stockholders receive cash in lieu of fractional shares.
Common stock begins trading on split-adjusted basis July 28, 2025 under ticker MRSN.
Authorized shares unchanged; proportionate adjustments made to equity awards and plans.
Split intended to bring company into compliance with Nasdaq minimum bid price requirement.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Mersana Therapeutics, Inc.: 1-for-25 reverse stock split effected via Certificate of Amendment to the Fifth Amended and Restated Certificate of Incorporation (effective 2025-07-25).

Change: charter amendment
Effective: 2025-07-25

Exact text from the filing

On July 24, 2025, Mersana Therapeutics, Inc. (the “Company”) filed a Certificate of Amendment to the Company’s Fifth Amended and Restated Certificate of Incorporation, as amended, (the “Certificate of Amendment”) with the Secretary of State of the State of Delaware, which will effect, as of 5:00 p.m. Eastern Time, on July 25, 2025 (the “Effective Time”), a 1-for-25 reverse stock split (the “Reverse Stock Split”) of the issued and outstanding shares of the Company’s common stock, $0.0001 par value per share (the “Common Stock”).

View on SEC.gov

Browse all governance changes →

Source: SEC EDGAR

accession 0001104659-25-070245

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.